Limits...
TOX expression in cutaneous B-cell lymphomas.

Schrader AM, Jansen PM, Willemze R - Arch. Dermatol. Res. (2016)

Bottom Line: Thymocyte selection-associated high-mobility group box (TOX) is aberrantly expressed in cutaneous T-cell lymphomas.In conclusion, TOX is expressed not only by neoplastic T-cells, but also by both reactive and neoplastic follicle center (germinal center) B-cells and a proportion of BCL6(+) PCDLBCL,LT and secondary cutaneous BCL6(+) DLBCL.The functional significance of TOX expression in reactive and neoplastic B-cells remains to be elucidated.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Leiden University Medical Center, P.O. box 9600, 2300 RC, Leiden, The Netherlands. a.m.r.schrader@lumc.nl.

ABSTRACT
Thymocyte selection-associated high-mobility group box (TOX) is aberrantly expressed in cutaneous T-cell lymphomas. In a recent study, TOX expression was noted unexpectedly in the follicle center (germinal center) B-cells of reactive lymph nodes and tonsils, used as external controls. To evaluate whether TOX is also expressed by cutaneous B-cell lymphomas, TOX immunohistochemistry was performed on skin biopsies of 44 patients with primary and secondary cutaneous B-cell proliferations. TOX was expressed not only in the reactive follicle center cells of lymph nodes, tonsils, cutaneous lymphoid hyperplasia, and primary cutaneous marginal zone lymphomas, but also by the neoplastic follicle center cells of 16/17 patients with primary cutaneous follicle center lymphoma (PCFCL) and 7/7 patients with cutaneous manifestations of systemic follicular lymphoma (FL). Notably, TOX showed a very similar expression pattern as BCL6, a marker of germinal center B-cells. In 4/10 patients with a BCL6(+) primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL,LT) and in 2/2 patients with a secondary cutaneous BCL6(+) diffuse large B-cell lymphoma (DLBCL), TOX was expressed by more than 50 % of the neoplastic B-cells. In contrast, in 3/3 BCL6(-) PCDLBCL,LT, TOX was completely negative or weakly expressed by a minor proportion of the neoplastic B-cells. In conclusion, TOX is expressed not only by neoplastic T-cells, but also by both reactive and neoplastic follicle center (germinal center) B-cells and a proportion of BCL6(+) PCDLBCL,LT and secondary cutaneous BCL6(+) DLBCL. The functional significance of TOX expression in reactive and neoplastic B-cells remains to be elucidated.

No MeSH data available.


Related in: MedlinePlus

Histopathology of a tonsil with reactive follicles. TOX (a) is expressed in reactive follicles, predominantly in centrocytes (inset) in a pattern similar to BCL6 (b), but also in some scattered lymphocytes in the interfollicular areas (selected regions). (a, b ×100, selected regions in a and b ×200 and inset in a ×400)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940438&req=5

Fig1: Histopathology of a tonsil with reactive follicles. TOX (a) is expressed in reactive follicles, predominantly in centrocytes (inset) in a pattern similar to BCL6 (b), but also in some scattered lymphocytes in the interfollicular areas (selected regions). (a, b ×100, selected regions in a and b ×200 and inset in a ×400)

Mentions: In the reactive lymph nodes and tonsils that were used as benign external controls, TOX was expressed in the follicular areas and by scattered small lymphocytes, probably T-cells, in the interfollicular areas (Fig. 1). In the follicular areas, the centrocytes showed moderate to strong nuclear TOX expression, while staining of the centroblasts was dim or absent. Serial sections showed that the distribution of TOX+ cells was very similar to that observed for BCL6, a marker for germinal center B-cells. The same expression pattern was observed in both cases of CLH.Fig. 1


TOX expression in cutaneous B-cell lymphomas.

Schrader AM, Jansen PM, Willemze R - Arch. Dermatol. Res. (2016)

Histopathology of a tonsil with reactive follicles. TOX (a) is expressed in reactive follicles, predominantly in centrocytes (inset) in a pattern similar to BCL6 (b), but also in some scattered lymphocytes in the interfollicular areas (selected regions). (a, b ×100, selected regions in a and b ×200 and inset in a ×400)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940438&req=5

Fig1: Histopathology of a tonsil with reactive follicles. TOX (a) is expressed in reactive follicles, predominantly in centrocytes (inset) in a pattern similar to BCL6 (b), but also in some scattered lymphocytes in the interfollicular areas (selected regions). (a, b ×100, selected regions in a and b ×200 and inset in a ×400)
Mentions: In the reactive lymph nodes and tonsils that were used as benign external controls, TOX was expressed in the follicular areas and by scattered small lymphocytes, probably T-cells, in the interfollicular areas (Fig. 1). In the follicular areas, the centrocytes showed moderate to strong nuclear TOX expression, while staining of the centroblasts was dim or absent. Serial sections showed that the distribution of TOX+ cells was very similar to that observed for BCL6, a marker for germinal center B-cells. The same expression pattern was observed in both cases of CLH.Fig. 1

Bottom Line: Thymocyte selection-associated high-mobility group box (TOX) is aberrantly expressed in cutaneous T-cell lymphomas.In conclusion, TOX is expressed not only by neoplastic T-cells, but also by both reactive and neoplastic follicle center (germinal center) B-cells and a proportion of BCL6(+) PCDLBCL,LT and secondary cutaneous BCL6(+) DLBCL.The functional significance of TOX expression in reactive and neoplastic B-cells remains to be elucidated.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Leiden University Medical Center, P.O. box 9600, 2300 RC, Leiden, The Netherlands. a.m.r.schrader@lumc.nl.

ABSTRACT
Thymocyte selection-associated high-mobility group box (TOX) is aberrantly expressed in cutaneous T-cell lymphomas. In a recent study, TOX expression was noted unexpectedly in the follicle center (germinal center) B-cells of reactive lymph nodes and tonsils, used as external controls. To evaluate whether TOX is also expressed by cutaneous B-cell lymphomas, TOX immunohistochemistry was performed on skin biopsies of 44 patients with primary and secondary cutaneous B-cell proliferations. TOX was expressed not only in the reactive follicle center cells of lymph nodes, tonsils, cutaneous lymphoid hyperplasia, and primary cutaneous marginal zone lymphomas, but also by the neoplastic follicle center cells of 16/17 patients with primary cutaneous follicle center lymphoma (PCFCL) and 7/7 patients with cutaneous manifestations of systemic follicular lymphoma (FL). Notably, TOX showed a very similar expression pattern as BCL6, a marker of germinal center B-cells. In 4/10 patients with a BCL6(+) primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL,LT) and in 2/2 patients with a secondary cutaneous BCL6(+) diffuse large B-cell lymphoma (DLBCL), TOX was expressed by more than 50 % of the neoplastic B-cells. In contrast, in 3/3 BCL6(-) PCDLBCL,LT, TOX was completely negative or weakly expressed by a minor proportion of the neoplastic B-cells. In conclusion, TOX is expressed not only by neoplastic T-cells, but also by both reactive and neoplastic follicle center (germinal center) B-cells and a proportion of BCL6(+) PCDLBCL,LT and secondary cutaneous BCL6(+) DLBCL. The functional significance of TOX expression in reactive and neoplastic B-cells remains to be elucidated.

No MeSH data available.


Related in: MedlinePlus